While predominantly approved for T2DM and obesity, GLP-1 RAs also hold promise for treating other conditions like heart and kidney disease, with ongoing research exploring additional therapeutic applications. These agonists exhibit diverse effects within different organ systems, influencing conditions such as psoriasis, polycystic ovarian syndrome (PCOS), thyroid disorders, neurodegenerative diseases, and cardiopulmonary dysfunction. This evidence concerns the gene GLP1R and polycystic ovary syndrome.